Curaleaf Asks Alberta Regulator to Halt Aurora's ATM, Citing 10.8% Dilution
CURLF sits 87% above its 52-week low of $5.4.
Summary
Curaleaf filed a formal application with the Alberta Securities Commission to halt Aurora's ATM program during its pending US$4.00 hostile offer, alleging the issuances have diluted Aurora shareholders by ~10.8% and increased the offer's cost by over US$11 million.
Key Events · M&A and Partnerships · CURLF
-
Formal ASC Application Filed
Curaleaf asked the Alberta Securities Commission to immediately halt Aurora's ATM share issuances while the US$4.00 offer remains outstanding, requesting an expedited hearing.
-
Dilution Quantified
Aurora issued ~2.81M shares at avg US$3.04 since June 2026, diluting shareholders ~4.9% in that period and ~10.8% since the ATM launched in February 2026.
-
Offer Cost Increased
The new shares raised the aggregate value required to complete Curaleaf's offer by more than US$11 million.
-
Defensive Tactic Allegation
Curaleaf argues Aurora's ATM use is an improper defensive tactic inconsistent with its claimed debt-free, C$149M cash position and 'strategic and accretive purposes only' ATM mandate.
Analysis · CURLF · Life Sciences
Curaleaf has escalated its hostile takeover fight by formally asking the Alberta Securities Commission to stop Aurora's at-the-market share issuance program while the US$4.00 offer remains open. The filing quantifies the damage: Aurora has issued about 2.81 million shares at an average US$3.04 since June 2026, raising the cost of Curaleaf's offer by more than US$11 million and diluting Aurora shareholders by roughly 10.8% since the ATM began in February 2026. This is a material escalation from the prior fact sheet because it moves from public criticism to a regulatory enforcement action with an expedited hearing request, directly targeting the defensive tactic Curaleaf says is undermining its bid.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CURLF was trading at $10.11 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $5.40 to $15.15. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.